Evaxion 6-K incorporates press release on EVX-01 phase 2 findings

Rhea-AI Filing Summary

Evaxion A/S furnished a Form 6-K that provides a company press release titled “Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01.”

The filing states that this report is incorporated by reference into Evaxion’s effective registration statements on Forms S-8, F-3, and F-1, making the press release part of those offerings’ prospectuses to the extent not later superseded.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On November 7, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number		Description
99.1		Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: November 7, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion (EVAX) disclose in this Form 6-K?

Evaxion furnished a press release announcing new immune data from a phase 2 trial of its AI-designed personalized cancer vaccine EVX-01.

When was the Evaxion press release issued?

The press release was issued on November 7, 2025.

Where can I find the press release referenced by Evaxion?

It is included as Exhibit 99.1 to the Form 6-K.

Does this 6-K affect Evaxion’s registration statements?

Yes. The report is incorporated by reference into Evaxion’s Forms S-8, F-3, and F-1, unless later superseded.

Which Evaxion program is mentioned in the 6-K?

The filing references EVX-01, an AI-designed personalized cancer vaccine, with new immune data from a phase 2 trial.

Does the 6-K include financial results or guidance?

No. The document furnishes a press release and notes incorporation by reference; it does not include financial tables or earnings data.